Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
3(20%)
Results Posted
33%(3 trials)

Phase Distribution

Ph phase_1
3
20%
Ph phase_4
6
40%
Ph phase_2
2
13%
Ph not_applicable
2
13%
Ph phase_3
1
7%

Phase Distribution

3

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
3(21.4%)
Phase 2Efficacy & side effects
2(14.3%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
6(42.9%)
N/ANon-phased studies
2(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

15

all time

Status Distribution
Active(3)
Completed(9)
Other(3)

Detailed Status

Completed9
unknown3
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
15
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (21.4%)
Phase 22 (14.3%)
Phase 31 (7.1%)
Phase 46 (42.9%)
N/A2 (14.3%)

Trials by Status

unknown320%
completed960%
recruiting320%

Recent Activity

3 active trials
Showing 5 of 15
recruitingphase_1

Lopinavir/Ritonavir in PLWH With High-Grade AIN

NCT05334004
completedphase_4

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

NCT01513122
recruitingphase_3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
recruitingphase_1

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

NCT05925140
completedphase_2

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals

NCT04499677
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05334004Phase 1

Lopinavir/Ritonavir in PLWH With High-Grade AIN

Recruiting
NCT01513122Phase 4

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

Completed
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT05925140Phase 1

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

Recruiting
NCT04499677Phase 2

FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals

Completed
NCT05024006Not Applicable

Public Health Emergency: SOLIDARITY TRIAL Philippines

Completed
NCT04779047Phase 4

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Unknown
NCT04376814Not Applicable

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

Completed
NCT04343768Phase 2

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Completed
NCT04350684Phase 4

Umifenovir in Hospitalized COVID-19 Patients

Unknown
NCT04350671Phase 4

Interferon Beta 1a in Hospitalized COVID-19 Patients

Unknown
NCT03070470Phase 1

CiPA Phase 1 ECG Biomarker Validation Study

Completed
NCT01662336

Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program

Completed
NCT00605098Phase 4

Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy

Completed
NCT01445223Phase 4

A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15